Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $14.5052W HIGH $19.92
Volume
7.18 K
Value Traded
124.65 K
Short % Float
-
+0.06%Week
-3.92%1 Month
-3.64%3 Month
+10.88%6 Month
-67.08%5 Year
-47.21%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
425.80 M
EPS (TTM)
-4.56
P/E Ratio
-
Ent. Value
160.26 M
Total Shares
24.34 M
Float Shares
-
Insiders
-
Institutions
0.58%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
PRTC Catalyst Timeline
Dated clinical, regulatory and corporate events for PureTech Health plc
Past FDA Catalysts and PDUFA Decisions
How PRTC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2024-12-31 | LYT-100 | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D36 / 100
Pipeline Score
$112M
Pipeline Value
Overvalued
Valuation Signal
4
Drugs Scored
0.3x
rNPV / MCap
PureTech Health plc faces pipeline headwinds (36/100), with $478M risk-adjusted pipeline value, led by LYT-200 in Metastatic Cancer (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LYT-200 Small moleculeCompletedNCT04666688 | Metastatic Cancer | Phase 2 | COMPLETED | 44 | Dec 1, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every PRTC program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| GlyphAllo | major depressive disorder | Phase 2b | 2026-03-26 | therapeutically relevant drug levels in humansRead More | PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in HumansRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PRTC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in PRTC for Q2 2026. | ||||
PRTC Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PRTC ranks across every disease it competes in
Competitive Position is a premium feature
See how PRTC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPRTC News
About PureTech Health plc
BIOPHARMAWATCH ELITE PLUS
Trade the next PRTC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime